| Literature DB >> 16809613 |
Manuela Gavina1, Marzia Belicchi, Barbara Rossi, Linda Ottoboni, Fabio Colombo, Mirella Meregalli, Maurizio Battistelli, Laura Forzenigo, Piero Biondetti, Federica Pisati, Daniele Parolini, Andrea Farini, Andrew C Issekutz, Nereo Bresolin, Franco Rustichelli, Gabriela Constantin, Yvan Torrente.
Abstract
Recently our group demonstrated the myogenic capacity of human CD133(+) cells isolated from peripheral blood when delivered in vivo through the arterial circulation into the muscle of dystrophic scid/mdx mice. CD133(+) stem cells express the adhesion molecules CD44, LFA-1, PSGL-1, alpha4-integrins, L-selectin, and chemokine receptor CCR7. Moreover these cells adhere in vitro to VCAM-1 spontaneously and after stimulation with CCL19. Importantly, after muscle exercise, we found that the expression of VCAM-1 is strongly up-regulated in dystrophic muscle vessels, whereas the number of rolling and firmly adhered CD133(+) stem cells significantly increased. Moreover, human dystrophin expression was significantly increased when muscle exercise was performed 24 hours before the intra-arterial injection of human CD133(+) cells. Finally, treatment of exercised dystrophic mice with anti-VCAM-1 antibodies led to a dramatic blockade of CD133(+) stem cell migration into the dystrophic muscle. Our results show for the first time that the expression of VCAM-1 on dystrophic muscle vessels induced by exercise controls muscle homing of human CD133(+) stem cells, opening new perspectives for a potential therapy of muscular dystrophy based on the intra-arterial delivery of CD133(+) stem cells.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16809613 DOI: 10.1182/blood-2006-04-018564
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113